Table 1.

Summary of AV7909 Efficacy: Survival

		Guinea Pig				NHP

		Study 1		Study 2		Study 1		Study 2

Vaccine	Dilution	Survival^a	Time to Death^b	Survival^a	Time to Death ^b	Survival^a	Time to Death ^b	Survival^a	Time to Death ^b
	1:4	100 (16/16) ^d	NA	NT	NT	100 (8/8) ^d	NA	100 (10/10) ^d	NA
	1:16	100 (16/16) ^d	NA	NT	NT	88(7/8) ^d	3.9	100 (9/9) ^d	NA
	1:32	NT	NT	100 (24/24) ^d	NA	NT	NT	NT	NT
AV7909^c	1:64	100 (16/16) ^d	NA	100 (22/22) ^d	NA	75 (6/8) ^d	4.4 (1.4)	80 (8/10) ^d	4.8 (0.1)
	1:96	NT	NT	100 (23/23) ^c,	NA	NT		30 (3/10)	4.7 (1.9)
	1:128	NT	NT	96 (23/24 ^d	5.9	75 (6/8) ^c	4.8 (1.4)	40 (4/10)	5.2 (1.3
	1:192	NT	NT	83 (19/23)^d	4.5 (0.6)	NT		10 (1/10)	3.8 (1.5)
	1:256	6 (1/14)	4.1 (1.0)	77 (17/22) ^d	4.6 (1.2)	25 (2/8)	5.0 (0.9)	11 (1/9)	5.4 (1.3)

	1:16	67 (10/15) ^d	7.5 (2.0)	NT	NT	88 (7/8) ^d	14.9	NT	NT
AVA	1:96	NT	NT	50 (12/24) ^d	6.0 (3.2)	NT	NT	NT	NT
	1:64	NT	NT	NT	NT	NT	NT	67 (6/9) ^d	4.0 (0.9)

Adjuvant/Saline^c	N/A	0 (0/15)	2.8 (0.4)	0 (0/12)	2.6 (1.4)	13 (1/8)	3.8 (1.6)	0 (0/10)	3.7 (1.1)

LD₅₀ equivalents		399 ± 111		336 ± 37		287 ± 87		178 ± 50

% Survival (Number Survived / Total Challenged), Equal numbers of males and females were vaccinated on Day 0. The initial group size was 16 and 24 in Guinea Pig Study 1 and 2 respectively and 8 and 10 NHP Study 1 and 2 respectively. In several groups animals died prior to the challenge due to a non-study related illness or injury, and were not included any further analyses.

Time to death = Days (Standard Deviation)

Study 1 control animals received adjuvant (250 μg CpG 7909 + 0.650 to 0.730 mg Alhydrogel in 0.5 mL) control. Study 2 control animals received 0.5mL saline administered IM.

p < 0.05 compared to the adjuvant group determined by two-sided Fisher’s exact test with Bonferroni-Holm adjustment for multiple comparisons.

N/A, not applicable, NT, Not tested